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Abstract
Background: Immunotherapy is currently being examined as a treatment modality for glioblastoma. Maintaining
an optimal total lymphocyte count (TLC) after radiotherapy (RT) and using temozolomide may be beneficial in
optimizing immunotherapy. However, conventional temozolomide-based chemoradiation is known to induce
immunosuppressive effects, including lymphopenia. Therefore, this study aimed to identify potential clinical predictors
of acute severe lymphopenia (ASL) in patients receiving chemoradiation for glioblastoma.
Methods: We identified patients with glioblastoma treated with RT plus temozolomide from 2006 to 2017.
ASL was defined as a TLC of < 500/μL within 3 months after initiating RT. Independent predictors of ASL
were determined using logistic regression.
Results: A total of 336 patients were evaluated. Three-dimensional conformal RT (3D-CRT) and intensity-modulated
RT (IMRT) were used in 186 (55.4%) and 150 patients (44.6%), respectively. TLC decreased during RT and remained
persistently low during the 1-year follow-up, whereas the levels of other blood cell types recovered. In total, 118
patients (35.1%) developed ASL. During a median follow-up of 19.3 months, patients with ASL showed significantly
worse overall survival than did those without ASL (median, 18.2 vs. 22.0 months; P = .028). Multivariable analysis
revealed that increased planning target volume (PTV) was independently associated with increased ASL incidence
(hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.00–1.03; P = .042), while IMRT was independently associated with
decreased ASL incidence (HR, 0.48; 95% CI, 0.27–0.87; P = .015). A propensity-matched comparison showed that the
incidence of ASL was lower with IMRT than with 3D-CRT (20% vs. 37%; P = .005).
Conclusions: IMRT and low PTV were significantly associated with decreased ASL incidence after RT plus temozolomide
for glioblastoma. An IMRT-based strategy is necessary to enhance treatment outcomes in the immune-oncology era.
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Background
Radiotherapy (RT)-induced lymphopenia (i.e., a reduction
in the total lymphocyte count [TLC]) has been reported in
various types of tumors, such as glioblastomas, pancreatic
cancer, and lung cancer [1–7]. Although radiation has local
effects, RT to peripheral organs can result in irradiation of
a substantial proportion of circulating lymphocytes during
multifraction treatments [8]. Recently, several studies have
demonstrated that partial brain RT can contribute to
systemic lymphopenia [5–8]. RT-induced lymphopenia is
associated with poor survival in patients with high-grade
gliomas who underwent standard therapy with RTand tem-
ozolomide [5, 6].
Despite multimodal treatment involving surgery, RT,
and temozolomide, glioblastoma has a poor prognosis
and almost all patients with glioblastoma eventually ex-
perience disease relapse [9]. Although repeat surgery,
re-irradiation, and pharmacological treatment have been
performed in the recurrent setting, evidence that any
therapeutic intervention has a major effect on survival is
lacking [10, 11]. Accordingly, different immunotherapy
modalities for glioblastoma are being actively investi-
gated, spurred on by advances in immuno-oncology
for other tumor types [12]. However, conventional
temozolomide-based chemoradiation has immunosup-
pressive effects, including lymphopenia [5, 6, 13]. As
lymphocytes are important mediators of the immune
response to cancer, such iatrogenic immunosuppres-
sion can limit the administration of immunotherapy.
In this context, identifying and modifying the factors
associated with RT-induced lymphopenia can help main-
tain an optimal TLC, which may facilitate a synergistic
effect between RT and immunotherapy. Accordingly,
maintaining an optimal TLC may effectively improve
treatment outcomes in patients with glioblastoma. There-
fore, this study aimed to examine the potential clinical
predictors of treatment-related lymphopenia in patients
with glioblastoma treated with RT plus temozolomide.
Methods
Patients
Between February 2006 and January 2017, we identified
consecutive patients with histologically confirmed
glioblastoma treated with temozolomide-based chemora-
diation. We excluded patients who received whole-brain
RT for gliomatosis cerebri or extensive disease, those who
received whole-ventricle RT with a suspicion of ventricu-
lar seeding, and those without peripheral blood cell count
results before and within 3months after initiating RT.
Treatments
Patients underwent either tumor resection or stereotactic
biopsy. Thereafter, all patients received concurrent chemo-
radiation with temozolomide (75mg/m2 of body surface
area per day, 7 days per week from the first to the last day
of RT), followed by six cycles of adjuvant temozolomide
(150–200mg/m2 for 5 days during each 28-day cycle).
Regarding the target volume, a limited field or a standard
field was used based on the physician’s preference [14]. The
gross tumor volumes (GTVs) in both fields comprised the
resection cavity and any residual contrast-enhancing
tumor on immediate postoperative magnetic resonance
imaging (MRI) scans obtained within 48 h after surgery.
When delineating the GTV, we added a 0.5–1-cm margin
to compensate for irregularity and uncertainty. The clin-
ical target volume (CTV) in the standard field included
peritumoral edema, which was detected on T2-weighted
fluid-attenuated inversion recovery postoperative MRI
scans (peritumoral edema + 1–1.5 cm margin). The CTV
in the limited field was delineated by adding a 1.5-cm
margin to the GTV, regardless of the presence of peritu-
moral edema. In the three-dimensional conformal RT
(3D-CRT) plan, a 3-mm margin—for setup uncertainty—
was applied to create the planning target volume (PTV).
PTV1 and PTV2 were defined as the CTV plus a 3-mm
margin and the GTV plus a 3-mm margin, respectively. In
3D-CRT, 46 Gy in 23 fractions to the PTV1 and a
sequential boost of 14 Gy in 7 fractions to the PTV2
were prescribed. No PTV margin was added in the
intensity-modulated RT (IMRT) plan, and the PTV1
and PTV2 were the same as the CTV and GTV,
respectively. Instead, when IMRT was administered,
megavoltage or kilovoltage cone-beam computed tomo-
graphy image guidance was performed before each treat-
ment session for all patients. In IMRT, 51Gy in 30
fractions to the PTV1 and 60Gy in 30 fractions to the
PTV2 were prescribed using a simultaneous integrated
boost technique.
Assessment of lymphopenia
Peripheral blood counts were typically assessed every
week during RT and then every 1–3 months after RT for
1 year. Lymphopenia was graded using the Common
Terminology Criteria for Adverse Events criteria, version
4.03. A TLC of the lower limit of the normal value to
800/μL was categorized as grade I, 800–500/μL as grade
2, 500–200/μL as grade 3, and < 200/μL as grade 4.
Acute severe lymphopenia (ASL) was defined as a TLC
of < 500/μL (grade 3/4 toxicity) within 3 months after
beginning RT, as previously described [7].
Assessment of other baseline characteristics
Subventricular zone involvement was assessed via pre-
operative MRI using a standardized spatial classification
system [15]. The extent of resection was evaluated
using immediate postoperative gadolinium-enhanced
T1-weighted MRI scans and was categorized as total
(absence of any visible contrast-enhanced portions),
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subtotal (≥90% of the tumor removed), partial (< 90% of
the tumor removed), or biopsy. The DNA methylation
status of the CpG islands on the MGMT promoter and
the IDH1-R132H mutation (IDH1 mutation) status
were also examined.
Statistical analysis
Overall survival (OS) rates were calculated from the start
date of treatment to the date of death or the latest
follow-up visit by using the Kaplan-Meier method and
compared using the log-rank test. Univariate and multi-
variate analyses using Cox and logistic regression were
performed to identify the predictors of OS and the
development of ASL, respectively. Factors with a P-value
of <.05 in the univariate analyses were included in the
subsequent multivariate analysis. All tests were
two-sided, and significance was set at P < .05. The
changes in blood cell counts over time were plotted
using the R package “hexbin” [16]. Propensity score
matching between the 3D-CRT and IMRT groups was
performed by using 1:1 nearest neighbor (greedy-type)
analysis with a caliper width of 0.2 standard deviations
of the logit distance measure by using the R package
“MatchIt” [17]. Matching covariates were selected based
on their potential impact on the development of ASL
according to logistic regression analysis. These covariates
included sex, extent of resection, IDH1 mutation, PTV1,
baseline TLC, and the cumulative dose of temozolomide.
All statistical analyses were performed using the Statis-
tical Package for Social Sciences version 23.0 (IBM SPSS
Statistics, Armonk, NY) and R software version 3.4.1 (R
Foundation for Statistical Computing, Vienna, Austria;
https://www.R-project.org/).
Results
Patients and treatments
Of 374 consecutive patients, we excluded 38 because
they received whole-brain RT for gliomatosis cerebri or
extensive disease (n = 20), received whole-ventricle RT
with a suspicion of ventricular seeding (n = 15), and had
no peripheral blood cell count results before and within
3 months after initiating RT (n = 3). Thus, 336 patients
who received partial brain RT were selected for the final
analysis. Tumor resection was performed in 314 patients
(93.5%), while stereotactic biopsy was performed in 22
(6.5%). Most patients (n = 331, 98.5%) received a con-
ventionally fractionated regimen with a total dose of 60
Gy in 30 fractions. Regarding the target volume, a lim-
ited field and a standard field were used in 49 (14.6%)
and 287 patients (85.4%), respectively. A total of 186
(55.4%) and 150 (44.6%) patients received 3D-CRT and
IMRT, respectively. Significant inter-group differences
were observed between the 3D-CRT and IMRT groups
in the age, sex, extent of resection, IDH1 mutation
status, PTV, and number of fractions (all P < .05). The
median PTV1 for the 3D-CRT and IMRT groups was
422 cm3 (range, 74–1080 cm3) and 375 cm3 (range,
71–1041 cm3), respectively (P < .001). The mean cumula-
tive dose of temozolomide for 3months since the start of
chemoradiation was not significantly different between
the groups (3497mg/m2 vs. 3684mg/m2; P = .117). The
baseline patient characteristics and treatment details are
provided in Table 1.
Blood cell counts
During the 1-year follow-up after the initiation of RT,
the median number of blood tests performed per patient
was 30 (range, 7–217). Changes in hemoglobin concen-
trations and blood cell counts, including those of white
blood cells, platelets, neutrophils, and lymphocytes, are
shown in Fig. 1. The TLC decreased during chemoradia-
tion and remained persistently low over the follow-up
period. In contrast, hemoglobin concentrations did not
decrease significantly after chemoradiation. The counts
of white blood cells, platelets, and neutrophils decreased
during chemoradiation but showed a tendency to im-
prove during a year of follow-up.
In total, 118 patients (35.1%) developed ASL. The median
TLC at baseline was 1370/μL (range, 300–3740/μL), with
3.0% of patients having grade ≥ 3 lymphopenia. At 1, 3, and
12months after the initiation of RT, the median TLC was
1020/μL (range, 110–3230/μL), 1120/μL (range, 170–3070/
μL), and 980/μL (range, 30–2680/μL), respectively, and
10.1, 5.5, and 10.3% of patients developed grade ≥ 3
lymphopenia.
Survival analysis
During a median follow-up of 19.3 months (range,
1.4–145.0 months), the median OS was 20.5 months.
Patients with ASL had significantly poorer OS than
did those without ASL (median, 18.2 vs. 22.0 months;
P = .028; Fig. 2a). On Cox regression multivariate ana-
lysis, lower age, total resection, IDH1 mutation, MGMT
methylation, and absence of subventricular zone involve-
ment significantly indicated favorable OS (all P < .05).
ASL was significantly associated with poorer OS on uni-
variate analysis (P = .028), but it lost its significance for
OS after adjustment for other confounders (P = .756;
Table 2). When Cox regression analyses were separately
conducted for the 3D-CRT and IMRT groups, ASL was
not an independent prognostic factor for OS in both
groups (Additional file 1: Tables S1 and S2).
When a subgroup of 15 patients who showed grade ≥ 3
lymphopenia at the 3-month time point was included in
the multivariate analysis, having grade ≥ 3 lymphopenia at
the 3-month time point was associated with poor OS after
adjustment for other confounders (hazard ratio [HR],
2.44; 95% confidence interval [CI], 1.42–4.19; P = .001;
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Additional file 1: Table S3). This subgroup also showed
worse OS than did patients who had no ASL or had re-
covered from ASL at the 3-month time point (median OS,
8.8 vs. 19.3 vs. 22.0months; P = .001; Fig. 2b).
Predictors of ASL
The results of univariate and multivariate logistic regres-
sion analyses for ASL are shown in Table 3. Among pa-
tient- and tumor-related factors, female sex (P < .001) and
subtotal or partial resection (P = .001) were independently
associated with increased ASL incidence. Among the
treatment-related factors, an increased PTV1 (per 10 cm3;
HR, 1.02; 95% CI, 1.00–1.03; P = .042) was independently
associated with increased ASL incidence. In contrast, the
use of IMRT (HR, 0.48; 95% CI, 0.27–0.87; P = .015) was
independently associated with decreased ASL incidence.
When patients were stratified according to the PTV1,
the incidence of ASL increased as the PTV1 increased.
In addition, in each PTV1 subgroup, patients treated
with IMRT had a lower ASL incidence. With a PTV1 of
< 200, 200–400, 400–600, and > 600 cm3, ASL developed
in 14, 18, 27, and 33% of patients in the IMRT group,
respectively, and in 25, 39, 52, and 53% of patients in the
3D-CRT group, respectively. In total, ASL developed in
Table 1 Patient and treatment characteristics
Total (n = 336) 3D-CRT (n = 186) IMRT (n = 150) P*
Age, years, median (range) 58 (16–79) 59 (16–79) 56 (16–79) 0.004
Sex, n (%)
Female 149 (44.3) 96 (51.6) 53 (35.3) 0.003
Male 187 (55.7) 90 (48.4) 97 (64.7)
KPS, n (%)
≤ 70 172 (51.2) 104 (55.9) 68 (45.3) 0.156
80 82 (24.4) 41 (22) 41 (27.3)
≥ 90 82 (24.4) 41 (22) 41 (27.3)
Extent of resection, n (%)
Total 206 (61.3) 109 (58.6) 97 (64.7) 0.009
Subtotal/Partial 108 (32.1) 70 (37.6) 38 (25.3)
Biopsy 22 (6.5) 7 (3.8) 15 (10)
IDH1 mutation, n (%)
No 250 (74.4) 117 (62.9) 133 (88.7) < 0.001
Yes 18 (5.4) 6 (3.2) 12 (8)
unknown 68 (20.2) 63 (33.9) 5 (3.3)
MGMT, n (%)
Unmethylated 212 (63.1) 115 (61.8) 97 (64.7) 0.592
Methylated 124 (36.9) 71 (38.2) 53 (35.3)
Subventriclular zone, n (%)
Uninvolved 206 (61.3) 122 (65.6) 84 (56) 0.073
Involved 130 (38.7) 64 (34.4) 66 (44)
PTV1 volume, cm3, median (range) 403 (71–1080) 422 (74–1080) 375 (71–1041) <.001
PTV2 volume, cm3, median (range) 113 (6–475) 119 (12–475) 103 (6–468) 0.002
Total dose, Gy, median (range) 60 (41–72.5) 60 (54–70) 60 (41–72.5) 0.073
No. of fractionation, median (range) 30 (15–35) 30 (23–35) 30 (15–33) <.001
Baseline TLC, /μL, median (range) 1370 (300–3740) 1365 (300–3740) 1385 (410–3640) 0.648
Baseline TLC, /μL, n (%)
< 1000 81 (24.1) 45 (24.2) 36 (24) 0.893
≥ 1000 255 (75.9) 141 (75.8) 114 (76)
The cumulative dose of temozolomidea, mg/m2, median (range) 3588 (722–6267) 3497 (856–6267) 3684 (722–5599) 0.117
Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target
volume, TLC total lymphocyte count
*P-values were calculated for the comparison of the 3D-CRT and IMRT groups
aThe cumulative doses of temozolomide for 3 months from the start of chemoradiation were calculated
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21.3 and 46.2% of the patients in the IMRT and 3D-CRT
groups, respectively (P < .001; Fig. 3a).
Propensity score matching was performed to adjust
for significant differences in the baseline characteris-
tics between the IMRT and 3D-CRT groups. After
matching, sex, extent of resection, IDH1 mutation,
PTV1, baseline TLC, and the cumulative dose of tem-
ozolomide were well balanced between the groups
(Additional file 1: Table S4). Among the 113 matched
pairs, ASL developed in 23 (20.4%) and 42 (37.2%)
patients in the IMRT and 3D-CRT groups, respect-
ively (P = .005). In each PTV1 subgroup among the
propensity-matched cohort, patients treated with
IMRT had a lower ASL incidence (Fig. 3b).
Discussion
In this study, we confirmed previous evidence regarding
treatment-induced lymphopenia by using a relatively large
population of patients with glioblastoma who received
standard RT and chemotherapy [5–7]. The present study
showed that cell counts of various blood cell types change
over time after chemoradiation. Among them, the de-
crease in the lymphocyte count after chemoradiation
persisted for a year, while other blood cell types, such as
white blood cells, platelets, and neutrophils, showed
recovery patterns and the count of red blood cells did not
decrease after chemoradiation. Grossman et al. [5]
showed that the CD4 count had the lowest value at 2
months after RT and remained persistently low after
temozolomide-based chemoradiation in 96 patients
with high-grade glioma. Moreover, this chronicity of
lymphopenia was consistent with the lymphopenia
pattern in other types of cancers such as pancreatic
cancer and lung cancer [1]. Our findings confirmed
such a pattern of treatment-related lymphopenia in 323
patients with glioblastoma and showed that this pattern
was unique to changes in the lymphocyte count.
The clinical significance of treatment-related lymphope-
nia in patients with glioblastoma has drawn more
attention in the modern immuno-oncology era. The thera-
peutic options for patients with recurrent glioblastoma are
currently limited, but repeat surgery, RT, and pharmaco-
logical treatment with alkylating agents or bevacizumab
have been performed [10, 11]. Nevertheless, a substantial
proportion of patients do not receive any second-line anti-
cancer therapy [18, 19]. Accordingly, different types of
immunotherapy are being actively examined as novel
Fig. 1 Scatter plot indicating changes in blood cell counts. Hemoglobin concentration (a), and white blood cell (b), platelet (c), neutrophil (d),
and lymphocyte counts (e) over the 1-year follow-up. Density was computed using the R package “hexbin,” with N = 35 bins partitioning the data
range. Compared with the count of the other blood cell types, the total lymphocyte count was markedly decreased after the start of radiotherapy (RT)
and remained low during the 1-year follow-up
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approaches for the treatment of recurrent glioblastoma,
including the glioblastoma vaccine, oncolytic viral therapy,
chimeric antigen receptor T-cell therapy, and immune-
checkpoint inhibitors [12]. For these immunotherapies, pre-
serving the optimal lymphocyte count is essential, as
lymphocytes play a fundamental role in cell-mediated im-
munologic destruction of cancers [20]. However, conven-
tional first-line therapies for glioblastoma, including RT and
temozolomide, have immunosuppressive effects. Moreover,
as shown in the TLC patterns after chemoradiation in our
study, the immunosuppressive effects can become chronic,
i.e., the effects can even limit the applicability of immuno-
therapy as a second-line treatment option after relapse that
mostly occurs after a few months or years. Therefore, ef-
forts to identify the risk factors for ASL are important for
establishing optimal chemoradiation strategies to preserve
the TLC, which may have a potential synergistic effect with
immunotherapy as a second-line treatment.
On examining various clinical and therapeutic factors,
we found that female sex, subtotal/partial resection, in-
creased PTV, and the use of 3D-CRT were independently
associated with the development of ASL. Interestingly, the
association between female sex and ASL has also been
shown in previous studies on temozolomide-based che-
moradiation for high-grade glioma [6, 7]. Although this
could be attributed to differences in the pharmacokinetics
and pharmacodynamics between sexes, the exact mechan-
ism remains unknown [21].
A mathematical computation model has supported the
association between local RT for body parts without the
bone marrow or lymphatic tissue and systemic lymphope-
nia [8]. This model demonstrated that the mean dose to
circulating lymphocytes is approximately 2 Gy and that
nearly all the circulating blood receives at least 0.5 Gy dur-
ing a typical course of RT for glioblastoma. Considering
that lymphocytes are the most radiosensitive cells among
all blood cell types and that the LD50 (lethal dose required
to reduce the surviving fraction of lymphocytes by 50%) is
only 2 Gy, this effect of RT on the circulating blood
volume can cause ASL [22]. This model also examined
two different PTVs (4.2 and 268 cm3) for glioblastoma and
showed a large difference in the percent of blood receiving
at least 0.5 Gy according to the target volume size. Our
study confirmed the finding of this theoretical model
regarding the effect of conventionally fractionated RT and
PTV size on treatment-related lymphopenia by using clin-
ical data of patients with glioblastoma.
We demonstrated that IMRT significantly reduced the
development of ASL in patients receiving a conventionally
fractionated regimen for glioblastoma. Compared to
3D-CRT, IMRT improves the dose distribution to the target
volume as well as reduces the dose to normal tissues, such
as normal brain tissues, optic structures, and the brain stem
[23]. We collected data on the low-dose distribution to the
brain and found that although V0.5 Gy and V3 Gy were not
significantly different between the 3D-CRT and IMRT
Fig. 2 Kaplan-Meier estimates of overall survival according to ASL (a), and ASL and TLC (b). ASL, acute severe lymphopenia; TLC, total
lymphocyte count
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groups, V5 Gy, V10 Gy, and V25 Gy were significantly lower in
the IMRT groups (Additional file 1: Table S5). However, the
irradiation volume of blood can become high in IMRT
because IMRT usually takes a longer time than 3D-CRT.
Accordingly, a precise mathematical method is needed to
calculate the accurate dose for individual cases, which
should be evaluated in further studies. IMRT has been
adopted for the routine clinical treatment of many types of
cancers including brain tumors [24]. However, compared to
the use of IMRT for head and neck cancer [25], the clinical
significance of IMRT for glioblastoma has not been well
established to date. In this study, we showed the benefit of
using IMRT for treating brain tumor in terms of preserving
immunity. As immunotherapy is rapidly evolving and can
be used in the future as a second-line treatment, IMRT can
be applied more actively for glioblastoma for the purpose of
preserving immunity.
Reduced TLC and reduced lymphocyte infiltration in
pathologic specimens are associated with poor OS [1, 3–5,
7, 26–29]. Several studies have also investigated the asso-
ciation between treatment-related lymphopenia and OS in
patients with glioblastoma [5–7], and have shown that
radiation-induced reduction of circulating lymphocyte
counts and subsequent lymphocyte infiltration of tumors
may have a tangible impact on OS outcomes [27, 30].
However, owing to the heterogeneous study population
and small number of patients, it was difficult to draw a
solid conclusion on the prognostic effect of RT-induced
lymphopenia in glioblastoma. In our study, although pa-
tients with ASL had poorer OS than did those without
ASL, ASL was not a significant factor on multivariate ana-
lysis. This inconsistency might be because our study in-
cluded well-established biomarkers such as IDH1 mutation,
MGMT methylation, and subventricular zone involvement,
while previous studies investigated none of these factors [5]
or only investigated MGMT methylation [6]. The inclusion
of strong prognostic factors [31–33] in our study could
have relatively diminished the prognostic significance of
ASL. However, when we included grade ≥ 3 lymphopenia at
the 3-month time point instead of ASL (grade ≥ 3 lympho-
penia at any time point within 3months) in the multivariate
analysis, the results showed that this alternative definition
Table 2 Univariate and multivariate Cox regression analyses for overall survival
Univariate HR (95% CI) P Multivariate HR (95% CI) P
Patient-related factor
Age (per 1 year) 1.01 (1.00–1.02) 0.005 1.02 (1.01–1.03) 0.003
Sex (Male vs. Female) 1.02 (0.80–1.30) 0.889
KPS
(80 vs. ≤70) 1.06 (0.79–1.42) 0.697
(≥90 vs. ≤70) 0.78 (0.58–1.06) 0.112
Baseline TLC (< 1000/μL vs. ≥1000/μL) 1.25 (0.94–1.64) 0.119
Tumor-related factor
Extent of resection
(Subtotal/Partial vs. Total) 1.78 (1.38–2.31) <.001 1.75 (1.33–2.31) <.001
(Biopsy vs. Total) 1.69 (1.06–2.70) 0.028 1.50 (0.93–2.43) 0.095
IDH1 mutation
(Yes vs. No) 0.25 (0.11–0.55) <.001 0.30 (0.13–0.69) 0.005
(Unknown vs. No) 1.14 (0.86–1.52) 0.360 0.97 (0.71–1.31) 0.818
MGMT (Methylated vs. Unmethylated) 0.46 (0.35–0.60) <.001 0.48 (0.37–0.63) <.001
Subventriclular zone (Involved vs. Uninvolved) 1.57 (1.23–2.01) <.001 1.52 (1.17–1.96) 0.001
Treatment-related factor
The cumulative dose of temozolomide (per 100 mg/m2) 1.00 (0.99–1.00) 0.260 1.00 (0.99–1.01) 0.597
PTV1 volume (per 10 cm3) 1.01 (1.00–1.01) 0.132
PTV2 volume (per 10 cm3) 1.02 (1.00–1.03) 0.029 1.01 (0.99–1.02) 0.305
Radiotherapy modality (IMRT vs. 3D-CRT) 0.91 (0.71–1.17) 0.483
Total dose (per 1 Gy) 0.98 (0.95–1.01) 0.187
No. of fractionation (per 1) 0.99 (0.94–1.05) 0.845
Acute severe lymphopenia (Yes vs. No) 1.32 (1.03–1.69) 0.028 1.04 (0.81–1.35) 0.756
Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky
performance status, PTV planning target volume, TLC total lymphocyte count
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Fig. 3 Incidence rates of ASL according to the PTV and radiotherapy modality. All patients (a); Propensity-matched patients (b). ASL, acute severe
lymphopenia; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; PTV, planning target volume
Table 3 Univariate and multivariate logistic regression analyses for acute severe lymphopenia
Univariate HR (95% CI) P Multivariate HR (95% CI) P
Patient-related factor
Age (per 1 year) 1.02 (1.00–1.03) 0.098
Sex (Male vs. Female) 0.30 (0.18–0.47) <.001 0.33 (0.19–0.55) <.001
KPS
(80 vs. ≤70) 0.90 (0.53–1.56) 0.716
(≥90 vs. ≤70) 0.54 (0.30–0.97) 0.038
Baseline TLC (< 1000/μL vs. ≥1000/μL) 1.83 (1.09–3.07) 0.021 1.69 (0.94–3.03) 0.082
Tumor-related factor
Extent of resection
(Subtotal/Partial vs. Total) 2.85 (1.75–4.64) <.001 2.40 (1.40–4.11) 0.001
(Biopsy vs. Total) 1.57 (0.62–3.94) 0.338 2.43 (0.84–6.98) 0.100
IDH1 mutation
(Yes vs. No) 0.64 (0.21–2.01) 0.447 0.75 (0.22–2.57) 0.649
(Unknown vs. No) 2.68 (1.56–4.64) <.001 1.83 (0.93–3.62) 0.079
MGMT (Methylated vs. Unmethylated) 0.69 (0.43–1.11) 0.122
Subventriclular zone (Involved vs. Uninvolved) 1.27 (0.80–2.00) 0.308
Treatment-related factor
The cumulative dose of temozolomide (per 100 mg/m2) 0.98 (0.97–1.00) 0.087 0.99 (0.97–1.02) 0.530
PTV1 volume (per 10 cm3) 1.02 (1.00–1.03) 0.012 1.02 (1.00–1.03) 0.042
PTV2 volume (per 10 cm3) 1.02 (1.00–1.05) 0.083
Radiotherapy modality (IMRT vs. 3D-CRT) 0.32 (0.19–0.51) <.001 0.48 (0.27–0.87) 0.015
Total dose (per 1 Gy) 0.95 (0.89–1.01) 0.072
No. of fractionation (per 1) 0.99 (0.90–1.08) 0.749
Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky
performance status, PTV planning target volume, TLC total lymphocyte count
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of lymphopenia was a strong independent prognostic factor
(Additional file 1: Table S3). This implies that recovery
from ASL may be a more important finding than the pre-
sence or absence of ASL. However, owing to a lack of
consensus and the use of different time points in defining
treatment-related lymphopenia across studies, efforts to
find the best definition of treatment-related lymphopenia
should be continued [30].
The main limitation of this study is that the margins
used to define the PTV differed between the IMRT and
3D-CRT groups. Nevertheless, we used the same defin-
ition of the GTV and CTV for both groups, and stan-
dardized target volume delineation was performed for all
patients. The incidence of ASL still showed a significant
difference after the PTV was balanced between both
groups by using propensity score matching. Because this
was a single-center retrospective study, there might have
been unrecognized biases that were not completely ad-
dressed by multivariate analysis or propensity score
matching. Therefore, our findings should be interpreted
keeping these limitations in mind.
Conclusions
This study revealed that although a large PTV can in-
crease the risk of ASL, IMRT can effectively lower the risk
of ASL after the initiation of RT plus temozolomide for
treating glioblastoma. Our findings add to the growing
evidence on the association between RT and
treatment-induced lymphopenia in patients with glioblast-
oma. Particularly, in cases with a large tumor size or surgi-
cal cavity, IMRT-based therapeutic strategies should be
actively considered to preserve the TLC. Such strategies
could potentially improve treatment outcomes in the
immuno-oncology era, and would thus need further study.
Additional file
Additional file 1: Table S1. Univariate and multivariate Cox regression
analyses for overall survival in the 3D-CRT group. Table S2. Univariate
and multivariate Cox regression analyses for overall survival in the IMRT
group. Table S3. Univariate and multivariate Cox regression analyses for
overall survival in all patients. Table S4. Covariates included in the
propensity score matching. Table S5. The dosimetric parameters for brain.
(DOCX 47 kb)
Abbreviations
3D-CRT: Three-dimensional conformal radiotherapy; ASL: Acute severe
lymphopenia; CI: Confidence interval; CTV: Clinical target volume; GTV: Gross
tumor volume; HR: Hazard ratio; IMRT: Intensity-modulated radiotherapy;
MRI: Magnetic resonance imaging; OS: Overall survival; PTV: Planning target
volume; RT: Radiotherapy; TLC: Total lymphocyte count
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